Immunotherapy for Basal Cell Carcinoma

Chen, Leon; Silapunt, Sirunya; Migden, Michael R.

doi:10.1007/978-3-030-26887-9_14

Cited by 3 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Source: Kappelin et al, (2020) like structures, massive blue-grey ovoid nests, and spoke-wheel areas (Cameron et al, 2019). The application of dermoscopy can enhance the precision of the diagnostic and provide variants of BCC's certain subtypes (Litaiem et al, 2020).…”

Section: Sizementioning

confidence: 99%

“…The hallmark of BCC on dermoscopy is the presence of well-targeted arborizing vessels. Additiona l findings encompass a couple of blue-grey globules, leaf-like structures, massive bluegrey ovoid nests, and spoke-wheel areas (Cameron et al, 2019). The application of dermoscopy can enhance the precision of the diagnostic and provide variants of BCC's certain subtypes (Litaiem et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A successfully treated Basal Cell Carcinoma using elliptical excision surgery

Citrashanty

Luthfidyaningrum²,

Ervianti³

et al. 2023

Qanun Medika

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is a non-keratinization cell-derived neoplasm. Surgical excision is the most common way to remove a tumor. The excision depends on the tumor type, size, and location. This paper reported a 44- years-old woman presented with the chief complaint of a single bump that bleeds easily in the facial region that began one year ago. Dermatology examination revealed hyperpigmented plaque with an ulcer in central, solitary, oval, 2 cm x 1 cm in size, covered with blackish crust on top. A Dermoscopy examination showed blue dots and globules, arborizing vessels, and ulceration. Histopathology examination findings were in concordance with BCC. The patient was treated with elliptical surgical excision. The lesion was successfully removed and showed good results with minimal scarring. BCC occurs in 75% of all skin cancers. Elliptical surgical excision on the left cheek was performed after considering the location anatomy, defect size, age, and general condition patient and postoperative cosmetic estimates. The minimal scar that occurs is planned to be performed with a fractional laser. The prognosis is generally good. There is no recurrence until one year later. In conclusion, elliptical surgical excision is an effective standard treatment if performed with a safe margin. In this case, we used 5 mm safe outer margin.

show abstract

Section: Sizementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A successfully treated Basal Cell Carcinoma using elliptical excision surgery

Citrashanty

Luthfidyaningrum²,

Ervianti³

et al. 2023

Qanun Medika

View full text Add to dashboard Cite

show abstract

“…Ipilimumab is an anti-CTLA4 monoclonal antibody (IgG1k) approved for melanoma and renal cell cancers (in monotherapy or in association with nivolumab). Currently, the recommended dosing for metastatic or unresectable melanoma is 3 mg/kg intravenously (IV) every 3 weeks for a total of 4 doses [ 27 ].…”

Section: The Role Of Immunotherapy In Non-melanoma Skin Cancermentioning

confidence: 99%

“…As far as concerns la-BCC and m-BCC, nivolumab use has been described in some cases, with a certain degree of response [ 56 , 88 ]. Currently, ongoing trials are investigating its efficacy for la-BCC and m-BCC administered in monotherapy or with ipilimumab (NCT03521830, NCT03816332, NCT02834013) [ 27 ]. Interestingly, another currently active trial investigates a combination of ablative fractioned laser plus topical nivolumab for BCCs (NCT04570683).…”

Section: The Role Of Immunotherapy In Non-melanoma Skin Cancermentioning

confidence: 99%

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Zelin

Maronese

Dri

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts.

show abstract

Systemic Therapy for Locally Advanced and Metastatic Non-Melanoma Skin Cancer

Chen

Migden

2021

Skin Cancer Management

View full text Add to dashboard Cite

Immunotherapy for Basal Cell Carcinoma

Cited by 3 publications

References 38 publications

A successfully treated Basal Cell Carcinoma using elliptical excision surgery

A successfully treated Basal Cell Carcinoma using elliptical excision surgery

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Systemic Therapy for Locally Advanced and Metastatic Non-Melanoma Skin Cancer

Contact Info

Product

Resources

About